Anti-Human CD52 (Alemtuzumab) – Dylight® 488
Anti-Human CD52 (Alemtuzumab) – Dylight® 488
Product No.: LT211
- -
- -
Product No.LT211 Clone Campath-1H Target CD52 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names HE5; CDW52; EDDM5 CDW52; Cambridge pathology 1 antigen Isotype Human IgG1κ Applications FA , FC , IHC FF , IHC FFPE |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human/Rhesus Monkey/Cynomolgus Monkey Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human lymphocytes. Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (493 nm) RRIDAB_2893946 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? IHC FFPE (Formalin-fixed paraffin-embedded tissue) IHC FF (Fresh Frozen) FA Additional Reported Applications For Relevant Conjugates ? CyTOF® WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only. Background Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects. Antigen Distribution CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars References & CitationsTechnical ProtocolsFA  IHC FF IHC FFPE Certificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LT200 | |
LT203 | |
LT204 | |
LT202 | |
LT201 | |
LT211 | |
LT206 | |
LT205 | |
LT207 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
